Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2008

View Archived Issues

EP4 receptor blocker may be useful in treating chronic arthritis

Mechanisms behind protective effects of KAI-9803 in stroke model determined

Glatiramer and steroid combination treatment beneficial in relapsing-remitting multiple sclerosis

GTx reports results from phase III clinical trial of toremifene citrate 80 mg

Recent Janssen patent discloses antiallergic and antiasthmatic agents

New local anesthetic compounds patented by PharmacoFore

Acambis initiates preclinical testing of dl5-29 HSV-2 vaccine

Bionomics initiates treatment in phase I clinical trial of BNC-105 anticancer drug

CollaGenex signs definitive merger agreement with Galderma

Verona Pharma plans clinical trials of RPL-554 for allergic respiratory diseases

Dr. Falk Pharma initiates phase II clinical study of Dong-A's udenafil for portal hypertension

ADVR signs research agreement with Northeastern University for AVR-118 in cancer

SV2A protein a target in partial and generalized epilepsy

Javelin completes subject accrual in the last of four phase I clinical studies of PMI-150

Health Canada approves Welichem Biotech's CTA for phase IIa clinical trial of WBI-1001

Actelion withdraws application to EMEA for extension of indication for Zavesca

Addex achieves preclinical milestone in agreement with Merck & Co. for allosteric modulators

ImmuPharma initiates dosing in phase IIb trial of IPP-201101 for systemic lupus erythematosus

Osiris reports interim results from phase I trial of Prochymal for myocardial infarction

Synthetic Blood awarded USD 1.9 million grant for phase IIb clinical trial of Oxycyte

Immunosyn reports results from proof-of-concept trial of SF-1019 for diabetic ulcers

VioQuest and the National Cancer Institute enter agreement for Akt inhibitor VQD-002

NPIL commences phase I P-1201-07 trials for metabolic disorders in Europe

FDA issues not approvable letter to Kyowa Hakko for istradefylline in Parkinson's

Novel antithrombotic agents described in recent Fournier and sanofi-aventis patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...